Oncopeptides will host a webcast in conjunction with its Year-end Report 2018 on 22 February at 14.00 (CET)

Stockholm —18 February 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Company will release its Year-end Report on 22 February at 8:00 am CET. The report will be available on the Company’s web site at www.oncopeptides.com.

The company's CEO Jakob Lindberg will summarize the financial year 2018 and address questions from investors, analysts and media.

An audiocast to the presentation will be available at:

https://tv.streamfabriken.com/oncopeptides-q4-2018 



  Time for webcast – 14.00 (CET) on 22 February
  

  Dial in number from Sweden: +46856642706                                        
  Dial in number from UK: +443333009270
  Dial in number US: +18335268382


For more information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 70 853 72 92
E-mail:
rein.piir@oncopeptides.com

This information was submitted for publication at 10.30 CET, 18 February 2018.

About Oncopeptides 

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), a novel peptide conjugated alkylator that selectively targets multiple myeloma belonging to the class of peptide-enhanced compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

More information is available on www.oncopeptides.com.

Tags:

About Us

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen, a novel peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in a global pivotal Phase 3 trial and in three additional supporting clinical trials. Oncopeptides’ headquarters is located in Stockholm, Sweden and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.